avVaa World Health Care Products Inc.

(Public, OTC:AVVH)

At this time we would like to announce that StocksHaven Investments and avVaa World Health Care Products Inc. have reached an agreement with regards to a six month investor relations contract. This contract includes three articles, two conference calls and ongoing company updates through our newsletter distribution services. Furthermore, on 9/23/09, Founder and Lead Investment Analyst, Michael Vlaicu has established a conference call with avVaa’s CEO, President and Director, Jack Farley. The exact time of the call has yet to be determined.

Moreover, StocksHaven Investments announces that they have opened up the option of submitting questions to be reviewed, which could lead to being asked during the interview process. Already included topics: future revenue projections, ongoing business operations, financial status, potential issues of

Imaging3, Inc.

(Public, OTC:IMGG)

A new and radical medical device from Imaging3 Inc. (OTC:IMGG) is ready to set the standard, and revolutionize the way we look at X-ray, MRI and CT scans. Imaging 3 is currently awaiting FDA approval on their DViS (Dominion Volumetric Imaging Scanner). Currently, medical imaging is met with challenges of long waits, lack of space, lack of mobility, and limited uses. However, for the first time ever, health-care workers will be able to instantly view 3D, high-resolution images of virtually any part of the human body. Thus, Imaging 3 looks to change all that. Saving time, saving lives and reducing costs. This technology will “set the standard for the next 10 years.” The following article was composed by StocksHaven Investments alongside Professor Philip Runfeldt, a Behavioral Analyst who has worked with Fortune 500 companies and major Universities throughout

Tired of missing out on StocksHaven Investments’ newest picks? Well now you don’t have to worry. We have recently just put together a special distribution list, and best of all – It’s FREE! Advantages: * Receive alerts well before articles are published & PR’d

* Company basics & fundamentals will be provided

* Speak directly with Founder and Lead Investment Analyst, Michael Vlaicu

* Ability to request technical & financial analysis To get in on this special distribution list, simply e-mail MichaelVlaicu@StocksHaven.com. Please include the title “Add me to special distribution list” along with your contact details. Random Posts Congratulations to everyone for big gains! Lung Cancer Medical Breakthrough (OTC:BMOD)

Adeona Pharmaceuticals, Inc.

(Public, AMEX:AEN)

StocksHaven Investments takes a look at Adeona Pharmaceuticals, Inc. which currently has three blockbuster drugs in phase III, and are coming close to NDA status. The first being Trimesta, which tackles Multiple Sclerosis (MS) and Post-partum Depression. Secondly, Zinthionein, a product seeking treatment for Age Related Macular Degeneration (AMD). Lastly, Oral dnaJP1 which is an immunotherapy for rheumatoid arthritis (RA) patients. If these products aren’t enough to entice your way into purchasing this stock, take a look at the recent $5 million dollar cash infusion from the National Multiple Sclerosis Society (NMSS), billions of dollars in product market potential, purchasing of Hartlab LLC, an independent Chicago-area CLIA-certified clinical reference laboratory, an experienced management team that will have you feeling like a kid in a candy store, and to

Nutra Pharma Corp.

(Public, OTC:NPHC)

StocksHaven Investments has confirmed they are set to profile Nutra Pharma Corp. in the coming days, and states that they have also touched base with with Investor Relations in regards to scheduling a tentative conference call with the Chairman and CEO, Rik J Deitsch. Nutra Pharma has recently made waves within the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. The company is also developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS).

Over 50 million Americans suffer from ongoing chronic pain, but that’s all about to change. In August, a biotechnology company, Nutra Pharma, shook the pain world when

Power3 Medical Products, Inc.

(Public, OTC:PWRM)

The following company analysis has been contributed by a StocksHaven Investments affiliate and member, Michael Sklar. He has been studying the markets for several years now with a focus in undiscovered Bio-Pharm companies.

About

Power3 Medical Products, Inc. (Power3) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. In the area of neurodegenerative diseases and breast cancer, Power3 has completed research and clinical validation studies involving over 1,500 patient samples. Power3 uses biostatistical analysis to monitor appropriate panels of biomarkers for diagnostic sensitivity and specificity for disease, normal and disease controls. By testing patient body fluids and tissues, including blood serum (for breast cancer and neurodegenerative diseases), and bone marrow aspirates (for leukemia patients), the Company

Derma Sciences, Inc.

(Public, OTC:DSCI)

Derma Sciences is a truly unique and highly undervalued company within the micro-cap biomed space which currently targets a prescription drug market that is about 5x its present market cap. The company is developing a patented topical drug for accelerated healing and scar prevention and newly launched Advanced Wound Care products approaching $10M, including the highly received MEDIHONEY, and BIOGUARD, both of which have garnered tremendeous success and continue to increase sales annually. The real gem however lies within their DSC127 phase II pipeline drug. Derma Sciences reported that it continues to move forward with clinical trials of DSC127, which has the potential to be only the second approved drug on the market for accelerated wound healing, a market with over $100M in sales anually.

About

Derma Sciences, Inc. is a fully integrated manufacturer, marketer and

Biomoda, Inc.

(Public, OTC:BMOD)

StocksHaven Investments profiles one of the most promising up and coming small cap biotech companies, Biomoda Inc, which has established a medical breakthrough for early lung cancer detection. It is a development-stage company. The Company is an invitro diagnostics company that develops assays, or tests, to detect cancer. These assays are performed in clinical reference laboratories using body-fluid samples. This technology is based on a licensed patent from Los Alamos National Laboratories. The technology is based on a molecule that has an affinity to bind with cancer cells and it fluoresces red under ultra violet light. It is a porphyrin molecule. This technology works with a range of cell types. The Company is in the process of developing a line of assays for a variety of cancers based on adaptations of this technology. Biomoda’s first product

INVO BioScience Inc

(Public, OTC:IVOB)

The following company analysis has been contributed by a StocksHaven Investments affiliate and member, Eric Sebastien. He is an entrepreneur with solid investment experience totalling fifteen years, and specializes in the small cap bio-tech field.

About

INVO BioScience Inc. (INVO Bioscience), formerly Emy’s Salsa Aji Distribution Company, Inc., is engaged in providing its INVOcell technology to help infertile couples have a baby. It has one principal product, the manufacturing and distribution of the INVOcell technology. The Company invoiced its first sales of the INVOcell selling 215 units along with 16 INVO Blocks during the year ended December 31, 2008. Further, it has signed contracts for the purchase of INVOcell devices in various countries, such as Turkey, Peru, Pakistan and Canada. On December 5, 2008, INVO Bioscience completed a reverse merger with Emy’s Salsa AJI Distribution Company,

At this time, StocksHaven Investments would like to recall and look back at the last few months of equity advice in order to showcase the proven track record. The following is a list of chosen companies which have been nothing short of stellar, giving investors much needed short term and long term gains despite the ongoing hostile recessionary environment.

1. Spongetech Delivery Systems, Inc. (+948% as of April/1/09) [ Article Link ]

2. Mesa Air Group, Inc. (+75% as of April/24/09) [ Article Link ]

3. Hemispherx Biopharma, Inc. (+ 52% as of May/8/09) [ Article Link ]